Dualyx, founded in 2020 and based in Zwijnaarde, Belgium, is focused on developing novel regulatory T cell (Treg)‑based therapies. Its lead program, DT‑001, is an antibody agonist targeting TNF receptor 2 (TNFR2) and is currently in IND‑enabling studies. The company has a pipeline of additional Treg‑targeting candidates and intends to advance these programs using newly raised capital. Dualyx was founded by Luc van Rompaey in a collaborative model with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven, and is led by CEO Wouter Verhoeven. The company emphasizes TNFR2 as a master control switch for immunosuppression in Treg therapies. Proceeds from the financing will be used to progress DT‑001 and the broader pipeline.

Total raised

$43M

Funding rounds

1

Latest round

Series A

Latest activity

May 2023